Posttransplant Medical Adherence: What Have We Learned and Can We Do Better?

  • Mary Amanda Dew
  • Donna M. Posluszny
  • Andrea F. DiMartini
  • Larissa Myaskovsky
  • Jennifer L. Steel
  • Annette J. DeVito Dabbs
Kidney Transplantation (M Henry and R Pelletier, Section Editors)
  • 8 Downloads
Part of the following topical collections:
  1. Topical Collection on Kidney Transplantation

Abstract

Purpose of review

Non-adherence to the medical regimen after kidney transplantation can contribute to poor clinical outcomes, and strategies to maximize adherence are sought by care providers and patients alike. We assessed recent evidence on prevalence, risk factors, and clinical outcomes associated with non-adherence to the medical regimen after kidney transplantation. We summarized recent clinical trials testing interventions to improve adherence and generated recommendations for future research and clinical practice.

Recent findings

A large evidence base documents rates of non-adherence to each of the multiple components of the regimen, including medication-taking, lifestyle activities, clinical care requirements, and substance use restrictions. Some risk factors for non-adherence are well known but the full range of risk factors remains unclear. Non-adherence to immunosuppressants and to other components of the regimen increases morbidity and mortality risks. Recent interventions, including education and counseling; electronic health strategies; and medication dose modifications, show promise for reducing immunosuppressant non-adherence. However, most of these interventions would be difficult to deploy in everyday clinical practice. Systematic dissemination of efficacious interventions into clinical practice has not been undertaken.

Summary

Rates and risk factors for non-adherence to the medical regimen have been examined and there is evidence that non-adherence may be ameliorated by a range of interventions. Although gaps in the evidence base remain, it would be timely to devote greater efforts to dissemination of findings. Thus, efforts are needed to assist transplant programs in using existing evidence to better identify patients who are non-adherent and to design and implement strategies to reduce or prevent non-adherence.

Keywords

Kidney transplantation Medical non-adherence Immunosuppressant non-adherence Substance use Risk factors Non-adherence interventions 

Notes

Acknowledgements

Preparation of this report was supported in part by Grants R01 DK101715 and R01 DK110737 from the National Institute of Diabetes and Digestive and Kidney Diseases.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance ••Of major importance

  1. 1.
    Dew MA, DeVito Dabbs A, Myaskovsky L, Shyu S, Shellmer DA, DiMartini AF, et al. Meta-analysis of medical regimen adherence outcomes in pediatric solid organ transplantation. Transplantation. 2009;88:736–46.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Dobbels F, Ruppar T, De Geest S, Decorte A, Van Damme-Lombaerts R, Fine RN. Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: a systematic review. Pediatr Transplant. 2010;14:603–13.PubMedGoogle Scholar
  3. 3.
    Tong A, Morton R, Howard K, Craig JC. Adolescent experiences following organ transplantation: a systematic review of qualitative studies. J Pediatr. 2008;155:542–9.Google Scholar
  4. 4.
    Yazigi NA. Adherence and the pediatric transplant patient. Sem Pediatr Surg. 2017;26:267–71.Google Scholar
  5. 5.
    • Belaiche S, Décaudin B, Dharancy S, Noel C, Odou P, Hazzan M. Factors relevant to medication non-adherence in kidney transplant: a systematic review. Int J Clin Pharm. 2017;39:582–93. Because this report described a systematic review, the paper provides a thorough description of the range of rates of nonadherence reported in the literature, and the risk factors that have been examined to date. However, it is difficult to interpret the information on adherence rates because the duration of observation time differed in each study (i.e., patients observed for longer would have more opportunity to demonstrate nonadherence than those with short observation time). PubMedGoogle Scholar
  6. 6.
    Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004;77:769–76.PubMedGoogle Scholar
  7. 7.
    Denhaerynck K, Dobbels F, Cleemput I, Desmyttere A, Schäfer-Keller P, Schaub S, et al. Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review. Transpl Int. 2005;18:1121–33.PubMedGoogle Scholar
  8. 8.
    Dew MA, DiMartini AF, DeVito Dabbs A, Myaskovsky L, Steel J, Unruh M, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation. 2007;83:858–73.PubMedGoogle Scholar
  9. 9.
    •• Kuypers DRJ, Peeters PC, Sennesael JJ, Kianda MN, Vrijens B, Kristanto P, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95:333–40. The authors report the results of a trial comparing once-daily dosing to conventional twice-daily dosing. Strengths of the study include the assessment of multiple aspects of medication-taking (e.g., doses taken, timing, drug holidays) and careful consideration of strengths and limitations of the trial. PubMedGoogle Scholar
  10. 10.
    • Lehner LJ, Reinke P, Horstrup JH, Rath T, Suwelack B, Kramer BK, et al. Evaluation of adherence and tolerability of prolonged-release tacrolimus (AdvagrafTM) in kidney transplant patients in Germany: a multicenter, noninterventional study. Clin Transplant. 2018;32:e13142. The authors build directly on the findings of the randomized clinical trial conducted by Kuypers et al. [9] in order to conduct an observational study of immunosuppressant medication adherence at multiple centers that have adopted once-daily dosing of tacrolimus. The report illustrates the direct application of clinical trial results to clinical practice, with evaluation of outcomes over 18 months of follow-up. Google Scholar
  11. 11.
    •• Duerinckx N, Burkhalter H, Engberg SJ, Kirsch M, Klem ML, Sereika SM, et al. Correlates and outcomes of posttransplant smoking in solid organ transplant recipients: a systematic literature review and meta-analysis. Transplantation. 2016;100:2252–63. This is a very thorough review and analysis of the evidence on posttransplant smoking, including consideration of numerous potential risk factors. Outcomes of smoking are also examined. It is difficult to interpret findings on rates of smoking because the duration of observation time differed in each study (i.e., patients observed for longer would have more opportunity to smoke than those with short observation time). PubMedGoogle Scholar
  12. 12.
    Parker R, Armstrong MJ, Corbett C, Day EJ, Neuberger JM. Alcohol and substance abuse in solid-organ transplant recipients. Transplantation. 2013;96:1015–24.PubMedGoogle Scholar
  13. 13.
    • Greenan G, Ahmad SB, Anders MG, Leeser A, Bromberg JS, Niederhaus SV. Recreational marijuana use is not associated with worse outcomes after renal transplantation. Clin Transplant. 2016;30:1340–6. Despite some methodologic limitations (reliance on unstructured clinical collection of data from self-report of marijuana use for some patients, single-center design, assumption that post-transplant marijuana use was identical to pre-transplant use), this is one of the few empirical examinations of marijuana use in transplant recipients. Google Scholar
  14. 14.
    Couzi L, Moulin B, Morin MP, Albano L, Godin M, Barrou B, et al. Factors predictive of medication nonadherence after renal transplantation: a French observational study. Transplantation. 2013;95:326–32.PubMedGoogle Scholar
  15. 15.
    De Geest S, Burkhalter H, Bogert L, Berben L, Glass TR, Denhaerynck K, et al. Describing the evolution of medication nonadherence from pretransplant until 3 years post-transplant and determining pretransplant medication nonadherence as risk factor for post-transplant nonadherence to immunosuppressives: the Swiss transplant cohort study. Transpl Int. 2014;27:657–66.PubMedGoogle Scholar
  16. 16.
    Nevins TE, Robiner WN, Thomas W. Predictive patterns of early medication adherence in renal transplantation. Transplantation. 2014;98:878–84.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Tsapepas D, Langone A, Chan L, Wiland A, McCague K, Chisholm-Burns M. A longitudinal assessment of adherence with immunosuppressive therapy following kidney transplantation from the mycophenolic acid observational renal transplant (MORE) study. Ann Transplant. 2014;19:174–81.PubMedGoogle Scholar
  18. 18.
    Middleton KR, Anton SD, Perri MG. Long-term adherence to health behavior change. Am J Lifestyle Med. 2013;7:395–404.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15:728–40.PubMedGoogle Scholar
  20. 20.
    Nevins TE, Nickerson PW, Dew MA. Understanding medication nonadherence after kidney transplant. J Am Soc Nephrol. 2017;28:2290–301.PubMedGoogle Scholar
  21. 21.
    Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:CD000011.Google Scholar
  22. 22.
    Nevins TE, Thomas W. Quantitative patterns of azathioprine adherence after renal transplantation. Transplantation. 2009;87:711–8.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Sabaté, E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization. 2003. http://apps.who.int/medicinedocs/pdf/s4883e/s4883e.pdf.
  24. 24.
    Fine RN, Becker Y, De Geest S, Eisen H, Ettenger R, Evans R, et al. Nonadherence consensus conference summary report. Am J Transplant. 2009;9:35–41.PubMedGoogle Scholar
  25. 25.
    •• Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, et al. Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the consensus on managing modifiable risk in transplantation (COMMIT) group. Transplantation. 2017;101(4S Suppl 2):S1–56. This document, written by experts in the field, summarizes evidence and recommendations for the management of kidney (as well as liver) recipients beyond the first year posttransplant. It is an essential document for both researchers and clinicians in the field. Google Scholar
  26. 26.
    Hurst FP, Altieri M, Patel PP, Jindal TR, Guy SR, Sidawy AN, et al. Effect of smoking on kidney transplant outcomes: analysis of the United States renal data system. Transplantation. 2011;92:1101–7.PubMedGoogle Scholar
  27. 27.
    Zelle DM, Agarwal PK, Ramirez JL, van der Heide JJ, Corpeleijn E, Gans RO, et al. Alcohol consumption, new onset of diabetes after transplantation, and all-cause mortality in renal transplant recipients. Transplantation. 2011;92:203–9.PubMedGoogle Scholar
  28. 28.
    Osterberg L, Blaschke T. Adherence to medication. New Engl J Med. 2005;353:487–97.PubMedGoogle Scholar
  29. 29.
    Gaynor JJ, Ciancio G, Guerra G, Sageshima J, Hanson L, Roth D, et al. Graft failure due to noncompliance among 628 kidney transplant recipients with long-term follow-up: a single-center observational study. Transplantation. 2014;97:925–33.PubMedGoogle Scholar
  30. 30.
    Israni AJ, Weng FL, Cen YY, Joffe M, Kamoun M, Feldman HI. Electronically-measured adherence to immunosuppressive medications and kidney function after deceased donor kidney transplantation. Clin Transpl. 2011;25:E124–31.Google Scholar
  31. 31.
    Taber DJ, Fleming JN, Fominaya CE, Gebregziabher M, Hunt KJ, Srinivas TR, et al. The impact of health care appointment non-adherence on graft outcomes in kidney transplantation. Am J Nephrol. 2017;45:91–8.PubMedGoogle Scholar
  32. 32.
    Patzer RE, Serper M, Reese PP, Przytula K, Koval R, Ladner DP, et al. Medication understanding, non-adherence, and clinical outcomes among adult kidney transplant recipients. Clin Transpl. 2016;30:1294–305.Google Scholar
  33. 33.
    Weng FL, Chandwani S, Kurtyka KM, Zacker C, Chisholm-Burns MA, Demissie K. Prevalence and correlates of medication non-adherence among kidney transplant recipients more than 6 months post-transplant: a cross-sectional study. BMC Nephrol. 2013;14:261.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Weng FL, Israni AK, Joffe MM, Hoy T, Gaughan CA, Newman M, et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol. 2005;16:1839–48.PubMedGoogle Scholar
  35. 35.
    Fierz K, Steiger J, Denhaerynck K, Dobbels F, Bock A, De Geest S. Prevalence, severity and correlates of alcohol use in adult renal transplant recipients. Clin Transpl. 2006;20:171–8.Google Scholar
  36. 36.
    • Ettenger R, Albrecht R, Alloway R, Belen O, Cavaillé-Coll MW, Chisholm-Burns MA, et al. FDA Public meeting on patient-focused drug development and medication adherence in solid organ transplant patients. Am J Transplant. 2018;18:564–73. This report summarizes a public meeting and scientific workshop held by the United States Food and Drug Administration, in which feedback from transplant recipients and family caregivers was obtained regarding costs and benefits associated with posttransplant medications. Experts summarized empirical evidence in the field. Comments from patient and family stakeholders are important for identifying issues to be addressed as new medications are developed for transplant recipients. Google Scholar
  37. 37.
    •• Jamieson NJ, Hanson CS, Josephson MA, Gordon EJ, Craig JC, Halleck F, et al. Motivations, challenges, and attitudes to self-management in kidney transplant recipients: a systematic review of qualitative studies. Am J Kidney Dis. 2016;67:461–78. A valuable systematic review of the qualitative literature examining patients’ perceptions of self-management issues related to the medical regimen after kidney transplantation. See also commentary by Dew and DeVito Dabbs [41]. PubMedGoogle Scholar
  38. 38.
    Tong A, Howell M, Wong G, Webster AC, Howard K, Craig J. The perspectives of kidney transplant recipients on medicine taking: a systematic review of qualitative studies. Nephrol Dial Transplant. 2011;26:344–54.PubMedGoogle Scholar
  39. 39.
    Marsicano EO, Fernandes Silva N, Marsicano EO, Fernandes NS, Colugnati FA, Fernandes NM, et al. Multilevel correlates of non-adherence in kidney transplant patients benefitting from full cost coverage for immunosuppressives: a cross-sectional study. PLoS One. 2015;10(11):e0138869.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Massey EK, Meys K, Kerner R, Weimar W, Roodnat J, Cransberg K. Young adult kidney transplant recipients: nonadherent and happy. Transplantation. 2015;99:e89–96.PubMedGoogle Scholar
  41. 41.
    Dew MA, DeVito Dabbs AJ. Harnessing the power of qualitative research in transplantation. Am J Kidney Dis. 2016;67:357–9.PubMedGoogle Scholar
  42. 42.
    Goodall DL, Willicombe M, McLean AG, Taube D. High intrapatient variability of tacrolimus levels and outpatient clinic nonattendance are associated with inferior outcomes in renal transplant patients. Transplant Direct. 2017;3:E192.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Scheel J, Reber S, Stoessel L, Waldmann E, Jank S, Eckardt KU, et al. Patient-reported non-adherence and immunosuppressant trough levels are associated with rejection after renal transplantation. BMC Nephrol. 2017;18:107.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Vanhove T, Vermeulen T, Annaert P, Lerut E, Kuypers DRJ. High intrapatient variability of tacrolimus concentrations predicts accelerated progression of chronic histologic lesions in renal recipients. Am J Transplant. 2016;16:2954–63.PubMedGoogle Scholar
  45. 45.
    O'Regan JA, Canney M, Connaughton DM, O'Kelly P, Williams Y, Collier G, et al. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation. J Nephrol. 2016;29:269–76.Google Scholar
  46. 46.
    Prihodova L, Nagyova I, Rosenberger J, Majernikova M, Roland R, Groothoff JW, et al. Adherence in patients in the first year after kidney transplantation and its impact on graft loss and mortality: a cross-sectional and prospective study. J Adv Nurs. 2014;70:2871–83.PubMedGoogle Scholar
  47. 47.
    Sapir-Pichhadze R, Wang Y, Famure O, Li Y, Kim SJ. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int. 2014;85:1404–11.PubMedGoogle Scholar
  48. 48.
    Shuker N, Shuker L, van Rosmalen J, Roodnat JI, Borra LC, Weimar W, et al. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. Transpl Int. 2016;29:1158–67.PubMedGoogle Scholar
  49. 49.
    Spivey CA, Chisholm-Burns MA, Damadzadeh B, Billheimer D, et al. Determining the effect of immunosuppressant adherence on graft failure risk among renal transplant recipients. Clin Transpl. 2014;28:96–104.Google Scholar
  50. 50.
    Lee SY, Chu SH, Oh EG, Huh KH. Low adherence to immunosuppressants is associated with symptom experience among kidney transplant recipients. Transplant Proc. 2015;47:2707–11.PubMedGoogle Scholar
  51. 51.
    Gheorghian A, Schnitzler MA, Axelrod DA, Kalsekar A, L'italien G, Lentine KL. The implications of acute rejection and reduced allograft function on health care expenditures in contemporary US kidney transplantation. Transplantation. 2012;94:241–9.PubMedGoogle Scholar
  52. 52.
    Sellarés J, deFreitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12:388–99.PubMedGoogle Scholar
  53. 53.
    Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157–67.PubMedGoogle Scholar
  54. 54.
    Wiebe C, Gibson IW, Blydt-Hansen TD, Pochinco D, Birk PE, Ho J, et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant. 2015;15:2921–30.PubMedGoogle Scholar
  55. 55.
    Wiebe C, Nickerson P. Strategic use of epitope matching to improve outcomes. Transplantation. 2016;100:2048–52.PubMedGoogle Scholar
  56. 56.
    •• Wiebe C, Rush DN, Nevins TE, Birk PE, Blydt-Hansen T, Gibson IW, et al. Class II eplet mismatch modulates tacrolimus trough levels required to present donor-specific antibody develop. J Am Soc Nephrol. 2017;28:3353–62. This paper, part of a series of important publications by Wiebe and colleagues [53–55], suggests the important role that adherence to immunosuppression plays in potentiating other biological factors that can lead to poor clinical outcomes in kidney recipients. PubMedGoogle Scholar
  57. 57.
    Takemoto SK, Pinsky BW, Schnitzler MA, Lentine KL, Willoughby LM, Burroughs TE, et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant. 2007;7:2704–11.PubMedGoogle Scholar
  58. 58.
    Taber DJ, Hunt KJ, Fominaya CE, Payne EH, Gebregziabher M, Srinivas TR, et al. Impact of cardiovascular risk factors on graft outcome disparities in black kidney transplant recipients. Hypertension. 2016;68:715–25.PubMedPubMedCentralGoogle Scholar
  59. 59.
    •• Rai HS, Winder GS. Marijuana use and organ transplantation: a review and implications for clinical practice. Curr Psychiatry Rep. 2017;19:91. This review provides a thorough and useful summary of both clinical observations and research evidence on the impact of marijuana use in transplant recipients. A valuable discussion is also provided on the issue of patient selection for transplantation and how marijuana use should be evaluated and considered in the selection process.Google Scholar
  60. 60.
    Thompson GR 3rd, Tuscano JM, Dennis M, Singapuri A, Libertini S, Gaudino R, et al. A microbiome assessment of medical marijuana. Clin Microbiol Infect. 2017;23:269–70.PubMedGoogle Scholar
  61. 61.
    Chisholm-Burns MA, Spivey CA, Graff Zivin J, Lee JK, Sredzinski E, Tolley EA. Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. Am J Transplant. 2013;13:2364–73.PubMedGoogle Scholar
  62. 62.
    Garcia MF, Bravin AM, Garcia PD, Contti MM, Nga HS, Takase HM, et al. Behavioral measures to reduce non-adherence in renal transplant recipients: a prospective randomized controlled trial. Int Urol Nephrol. 2015;47:1899–905.PubMedGoogle Scholar
  63. 63.
    Bessa AB, Felipe CR, Hannun P, Sayuri P, Felix MJ, Ruppel P, et al. Prospective randomized trial investigating the influence of pharmaceutical care on the intra-individual variability of tacrolimus concentrations early after kidney transplant. Ther Drug Monit. 2016;38:447–55.Google Scholar
  64. 64.
    • Breu-Dejean N, Driot D, Dupouy J, Lapeyre-Mestre M, Rostaing L. Efficacy of psychoeducational intervention on allograft function in kidney transplant patients: 10-year results of a prospective randomized study. Exp Clin Transplant. 2016;14:38–44. This trial is noteworthy for its relatively long clinical follow-up after conclusion of the intervention. Although the intervention resulted in better adherence than that in the comparison group, there was no demonstrable impact on clinical outcomes. This suggests that additional (or more prolonged) intervention strategies may be needed in order to sustain any adherence improvements. PubMedGoogle Scholar
  65. 65.
    Cukor D, Ver Halen N, Pencille M, Tedla F, Salifu M. A pilot randomized controlled trial to promote immunosuppressant adherence in adult kidney transplant recipients. Nephron. 2017;135:6–14.PubMedGoogle Scholar
  66. 66.
    McGillicuddy JW, Gregoski MJ, Weiland AK, Rock RA, Brunner-Jackson BM, Patel SK, et al. Mobile health medication adherence and blood pressure control in renal transplant recipients: a proof-of-concept randomized controlled trial. JMIR Res Protoc. 2013;2:E32.PubMedPubMedCentralGoogle Scholar
  67. 67.
    • Reese PP, Bloom RD, Trofe-Clark J, Mussell A, Leidy D, Levsky S, et al. Automated reminders and physician notification to promote immunosuppression adherence among kidney transplant recipients: a randomized trial. Am J Kidney Dis. 2017;69:400–9. This trial examined an intervention with monitoring of patient medication-taking, customized reminders to patients to take medications, and provider notification if adherence worsened. The intervention is potentially useful for routine clinical practice. PubMedGoogle Scholar
  68. 68.
    • Schmid A, Hils S, Kramer-Zucker A, Bogatyreva L, Hauschke D, De Geest S, et al. Telemedically supported case management of living-donor renal transplant recipients to optimize routine evidence-based aftercare: a single-center randomized controlled trial. Am J Transplant. 2017;17:1594–605. This trial examined not only medication adherence but quality of life and return to work. The trial examined an intervention that may usable in routine clinical practice, adding to the practical and clinical significance of the work. PubMedGoogle Scholar
  69. 69.
    • Mathes T, Großpietsch K, Neugebauer EAM, Pieper D. Interventions to increase adherence in patients taking immunosuppressive drugs after kidney transplantation: a systematic review of controlled trials. Syst Rev. 2017;6(1):236. This review encompasses studies conducted over the past several decades that have focused on interventions to improve immunosuppressant adherence after kidney transplantation. It includes clinical trials as well as other cohort studies. PubMedPubMedCentralGoogle Scholar
  70. 70.
    • Dew MA, DeVito Dabbs AJ, Posluszny DM, DiMartini AF. Adherence and self-management in the context of chronic disease: transplantation. In: Howren MB, Christensen AJ, editors. Patient adherence to medical treatment regimens and health lifestyle behaviors: Promoting evidence-based research and practice. New York: Springer Publishing, in press. This chapter provides a review of clinical issues and research findings regarding adherence to all aspects of the medical regimen after either kidney, liver, heart, or lung transplantation. Google Scholar
  71. 71.
    McGillicuddy JW, Taber DJ, Mueller M, Patel S, Baliga PK, Chavin KD, et al. Sustainability of improvements in medication adherence through a mobile health intervention. Prog Transplant. 2015;25:217–23.PubMedGoogle Scholar
  72. 72.
    Lorenz EC, Amer H, Dean PG, Stegall MD, Cosio FG, Cheville AL. Adherence to a pedometer-based physical activity intervention following kidney transplant and impact on metabolic parameters. Clin Transpl. 2015;29:560–8.Google Scholar
  73. 73.
    Tzvetanov I, West-Thielke P, D'Amico G, Johnsen M, Ladik A, Hachaj G, et al. A novel and personalized rehabilitation program for obese kidney transplant recipients. Transplant Proc. 2014;46:3431–7.PubMedGoogle Scholar
  74. 74.
    Pita-Fernández S, Seijo-Bestilleiro R, Pértega-Díaz S, Alonso-Hernández Á, Fernández-Rivera C, Cao-López M, et al. A randomized clinical trial to determine the effectiveness of CO-oximetry and anti-smoking brief advice in a cohort of kidney transplant patients who smoke: study protocol for a randomized controlled trial. Trials. 2016;17:174.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Dobbels F, Vanhoof J, Schoemans H, Duerinckx N, Verbeeck I, De Geest S. Improving medication adherence: the proof of the pudding will be in the eating. Liver Transpl. 2018;24:9–11.PubMedGoogle Scholar
  76. 76.
    •• Fleming JN, Taber DJ, McEllligott J, McGillicuddy JW, Treiber F. Mobile health in solid organ transplant: the time is now. Am J Transplant. 2017;17:2263–76. This narrative review considers recent evidence on use of mobile health interventions and activities in organ transplantation research and potential uses of such interventions in clinical practice. Gaps in both evidence and practice are noted. PubMedGoogle Scholar
  77. 77.
    • Thakkar J, Kurup R, Laba TL, Santo K, Thiagalingam A, Rodgers A. Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis. JAMA Intern Med. 2016;176:340–9. Although this work is not focused on kidney transplantation, it is a high-quality review and meta-analysis of the use of text messaging with implications for clinical care of kidney recipients. PubMedGoogle Scholar
  78. 78.
    DeVito Dabbs AD, Myers BA, McCurry KR, Dunbar-Jacob J, Hawkins RP, Begey A, et al. User-centered design and interactive health technologies for patients. Comput Inform Nurs. 2009;27:175–83.Google Scholar
  79. 79.
    Vanhoof JMM, Vandenberghe B, Geerts D, Philippaerts P, De Mazière P, DeVito Dabbs A, et al. Technology experience of solid organ transplant patients and their overall willingness to use interactive health technology. J Nurs Scholarsh.Google Scholar
  80. 80.
    •• Kidney Disease: Improving Global outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–157. A critical document produced by experts in the field addressing clinical issues in the care of kidney recipients. Google Scholar
  81. 81.
    Berben L, Dobbels F, Kugler C, Russell CL, De Geest S. Interventions used by health care professionals to enhance medication adherence in transplant patients: a survey of current clinical practice. Prog Transplant. 2011;21:322–31.PubMedGoogle Scholar
  82. 82.
    • Oberlin SR, Parente ST, Pruett TL. Improving medication adherence among kidney transplant recipients: findings from other industries, patient engagement, and behavioral economics—a scoping review. Sage Open Med. 2016;4:2050312115625026. The authors examined medical, social sciences and business-related literatures in order to identify factors linked to improved adherence to medications. Specific recommendations are offered for transplant programs seeking to improve their care to kidney recipients, especially with regard to identifying and helping patients to adhere to their medical regimens. PubMedPubMedCentralGoogle Scholar
  83. 83.
    Daudt HM, van Mossel C, Scott SJ. Enhancing the scoping study methodology: a large, inter-professional team’s experience with Arksey and O’Malley’s framework. BMC Med Res Methodol. 2013;13:48.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Glasgow RE, Vinson C, Chambers D, Khoury MJ, Kaplan RM, Hunter C. National Institutes of Health approaches to dissemination and implementation science: current and future directions. Am J Public Health. 2012;102:1274–81.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Chisholm MA, Lance CE, Williamson GM, Mulloy LL. Development and validation of the immunosuppressant therapy adherence instrument (ITAS). Patient Ed Couns. 2005;59:13–20.Google Scholar
  86. 86.
    Shäfer-Keller P, Steiger J, Bock A, Denhaerynck K, De Geest S. Diagnostic accuracy of measurement methods to assess non-adherence to immunosuppressive drugs in kidney transplant recipients. Am J Transplant. 2008;8:616–26.Google Scholar
  87. 87.
    Supelana C, Annunziato R, Schiano T, Anand R, Vaidya S, Chuang K, et al. The medication level variability index (MLVI) predicts rejection, possibly due to nonadherence, in adult liver transplant recipients. Liver Transpl. 2014;20:1168–77.PubMedCentralGoogle Scholar
  88. 88.
    Maclean JR, Pfister M, Zhou Z, Roy A, Tuomari VA, Heifets M. Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants. Ther Clin Risk Manag. 2011;7:149–56.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Craig C, Marshall A, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exer. 2003;35:1381–95.Google Scholar
  90. 90.
    Department of Health (UK). The general practice physical activity questionnaire: a screening tool to assess adult physical activity levels, within primary care. 2009 https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/192453/GPPAQ_-_guidance.pdf.
  91. 91.
    Segal-Isaacson CJ, Wylie-Rosett J, Gans KM. Validation of a short dietary assessment questionnaire: the rapid eating and activity assessment for participants short version (REAP-S). Diabetes Educ. 2004;30:774–10.PubMedGoogle Scholar
  92. 92.
    Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict. 1991;86:1119–27.PubMedGoogle Scholar
  93. 93.
    Ebbert JO, Patten CA, Schroeder DR. The Fagerström test for nicotine dependence-smokeless tobacco (FTND-ST). Addict Behav. 2006;31:1716–21.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry. 1974;131:1121–3.PubMedGoogle Scholar
  95. 95.
    Selzer ML. The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Psychiatry. 1971;127:1653–8.PubMedGoogle Scholar
  96. 96.
    Selzer ML, Vinokur A, van Rooijan L. A self-administered short Michigan alcoholism screening test (SMAST). J Stud Alcohol. 1975;36:117–26.PubMedGoogle Scholar
  97. 97.
    Pokorny AD, Miller BA, Kaplan HB. The brief MAST: a shortened version of the Michigan alcoholism screening test. Am J Psychiatry. 1972;129:342–5.PubMedGoogle Scholar
  98. 98.
    Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction. 1993;88:791–804.PubMedGoogle Scholar
  99. 99.
    Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158:1789–95.PubMedGoogle Scholar
  100. 100.
    Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med. 2010;170:1155–60.PubMedPubMedCentralGoogle Scholar
  101. 101.
    Skinner HA. The drug abuse screening test. Addict Behav. 1982;7:363–71.PubMedGoogle Scholar
  102. 102.
    Yudko E, Lozhkina O, Fouts A. A comprehensive review of the psychometric properties of the drug abuse screening test. J Subst Abus Treat. 2007;32:189–98.Google Scholar
  103. 103.
    WHO ASSIST Working Group. The alcohol, smoking and substance involvement screening test (ASSIST): development, reliability and feasibility. Addiction. 2002;97:1183–94.Google Scholar
  104. 104.
    Brown RL, Rounds LA. Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. Wis Med J. 1995;94:135–40.PubMedGoogle Scholar
  105. 105.
    Bastiaens L, Riccardi K, Sakhrani D. The RAFFT as a screening tool for adult substance use disorders. Am J Drug Alcohol Abuse. 2002;28:681–91.PubMedGoogle Scholar
  106. 106.
    Richter L, Johnson PB. Current methods of assessing substance use: a review of strengths, problems, and developments. J Drug Issues. 2001;31:809–32.Google Scholar
  107. 107.
    Grigsby TJ, Sussman S, Chou CP, Ames SL. Assessment of substance misuse. In: VanGeest JB, Johnson TP, Alemagno SA, editors. Research methods in the study of substance abuse. Cham: Springer; 2017. p. 197–234.Google Scholar
  108. 108.
    Corbett C, Armstrong MJ, Neuberger J. Tobacco smoking and solid organ transplantation. Transplantation. 2012;94:979–87.PubMedGoogle Scholar
  109. 109.
    DiMartini AF, Dew MA, Crone C. Organ transplantation. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan and Sadock’s comprehensive textbook of psychiatry, 10th ed. Philadelphia: Wolters Kluwer; 2017. p. 2357–73.Google Scholar
  110. 110.
    Park LG, Howie-Esquivel J, Dracup K. Electronic measurement of medication adherence. West J Nurs Res. 2015;37:28–49.PubMedGoogle Scholar
  111. 111.
    •• Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015;5:470–82. This report, prepared by experts in the field, carefully evaluates the pros and cons of using self-report measures of adherence and makes recommendations on optimal use in different research and clinical scenarios. It is a must-read paper for researchers and clinicians. PubMedPubMedCentralGoogle Scholar
  112. 112.
    Dobbels F, Berben L, De Geest S, Drent G, Lennerling A, Whittaker C, et al. The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: a systematic review. Transplantation. 2010;90:205–19.PubMedGoogle Scholar
  113. 113.
    DiMartini A, Day N, Dew MA, Lane T, Fitzgerald MG, Magill J, et al. Alcohol use following liver transplantation: a comparison of follow-up methods. Psychosomatics. 2001;42:55–62.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Mary Amanda Dew
    • 1
    • 2
  • Donna M. Posluszny
    • 3
  • Andrea F. DiMartini
    • 4
  • Larissa Myaskovsky
    • 5
  • Jennifer L. Steel
    • 6
  • Annette J. DeVito Dabbs
    • 7
  1. 1.Department of PsychiatryUniversity of Pittsburgh School of Medicine and Medical CenterPittsburghUSA
  2. 2.Departments of Psychiatry, Psychology, Epidemiology, Biostatistics, and the Clinical and Translational Science InstituteUniversity of PittsburghPittsburghUSA
  3. 3.Department of Medicine and University of Pittsburgh Medical Center Hillman Cancer CenterUniversity of PittsburghPittsburghUSA
  4. 4.Departments of Psychiatry and Surgery and the Clinical and Translational Science InstituteUniversity of PittsburghPittsburghUSA
  5. 5.Department of Internal Medicine, Nephrology Division, and the Center for Healthcare Equity in Kidney Disease, School of MedicineUniversity of New MexicoAlbuquerqueUSA
  6. 6.Departments of Surgery, Psychiatry, and PsychologyUniversity of PittsburghPittsburghUSA
  7. 7.Department of Acute and Tertiary Care, School of NursingUniversity of PittsburghPittsburghUSA

Personalised recommendations